Why the study?
Clinical guidelines increasingly recommend ambulatory blood pressure monitoring (ABPM), but it is used infrequently in the United States, possibly due to low insurance coverage and high patient costs.
What are the out-of-pocket payments for ambulatory blood pressure monitoring among commercially insured patients in the United States?
What are the out-of-pocket payments for ambulatory blood pressure monitoring among commercially insured patients in the United States?
Nearly 40% of commercially insured patients in the US incur out-of-pocket costs for ambulatory blood pressure monitoring, highlighting a potential economic barrier to guideline-recommended care.
38% of commercially insured patients incur OPP for ABPM (median $23); leaves open whether cost-sharing limits uptake.
BACKGROUND: Clinical guidelines increasingly recommended ambulatory blood pressure monitoring (ABPM) for hypertension diagnosis and management. Yet, ABPM is used infrequently in the United States, possibly because of low insurance coverage and high patient costs. We sought to analyze out-of-pocket payments (OPPs) for ABPM among privately insured patients. METHODS: We conducted a retrospective analysis using IBM® MarketScan® commercial claims of beneficiaries aged ≥18 years receiving ABPM from January 2012 to December 2018. The date of first ABPM claim (Healthcare Common Procedure Coding System codes 93784, 93786, 93788, or 93790) was considered the index date. Patients with 12 months of continuous enrollment preindex and 30-day postindex were included. Per beneficiary OPP was calculated by aggregating all ABPM-related OPPs within the 30-day postindex window (ABPM episode). RESULTS: Of 22,317 beneficiaries receiving ABPM, 62% had $0 OPP and 38% had OPP >$0. Among the latter, median OPP per beneficiary for an ABPM episode was $23 (interquartile range [IQR], $14, $32), driven primarily by full ABPM claims (median, $22; IQR, $14, $24). Among individual components, scan analysis and report claims (median, $25; IQR, $13, $49) had the greatest OPP. The median OPP per ABPM episode did not change substantively from 2012 through 2018. CONCLUSIONS: Among commercially insured in the United States, nearly 4-in-10 have an OPP for ABPM. Though most OPPs are relatively modest, some patients incur substantial OPP. Our findings highlight the need for policymakers to ensure adequate ABPM coverage in the commercial insurance marketplace.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: